WAYNE, Pa.--(BUSINESS WIRE)--Covalent Group, Inc. (Nasdaq: CVGR), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world’s leading pharmaceutical and biotechnology companies, announced today the signing of multiple Phase 1 and Phase 2 contracts having an aggregate value of $8.2 million. All of the contracts are with the same client and relate to the development of a potentially important agent to treat multiple types of influenza, including Avian Flu. Services include consulting on clinical trial design and protocol development, project and study site management, field operations, data management, and biostatistical support. Revenue recognition began during the recently completed third quarter and will continue on a proportional performance basis over the life of the contract as services are performed.
